Status:
COMPLETED
2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-091)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Postoperative Nausea and Vomiting
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to assess the safety and efficacy of 2 doses of an approved drug for a new indication in the prevention of postoperative nausea and vomiting in patients receiving general ...
Detailed Description
The duration of treatment is 4 weeks.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patient is at least 18 years of age.
- Patient is scheduled to undergo open abdominal surgery requiring overnight hospital stay (24-hour hospital stay after end of surgery).
- Patient is scheduled to receive general anesthesia.
- Patient is scheduled to receive postoperative opioids.
Exclusion
Key Trial Info
Start Date :
May 13 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 20 2005
Estimated Enrollment :
922 Patients enrolled
Trial Details
Trial ID
NCT00090246
Start Date
May 13 2004
End Date
April 20 2005
Last Update
May 5 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.